Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Januvia Archives
Print | Email | Share | Comments (0)

Merck Announces FDA Acceptance of NDA for Januvia


May 1, 2006

An investigational once-daily medicine for the treatment of type 2 diabetes

By October of this year, Merck & Co., Inc., expects the FDA to rule on its novel type 2 drug Januvia (sitagliptin phosphate). On February 15, 2006, the FDA accepted Merck’s New Drug Application (NDA) for Januvia for standard review.

Januvia is an investigational once-daily medicine for the treatment of type 2 diabetes. Merck says that if approved, Januvia would be the first in a new class of oral medications called DPP-4 inhibitors, which enhance the body’s own ability to lower blood glucose when it is elevated.

“Based on our clinical studies, we believe Januvia represents a new and different approach to the treatment of type 2 diabetes,” says Richard T. Clark, Merck’s chief executive officer and president. “Merck is committed to developing innovative therapies that offer advances in the treatment of serious diseases like diabetes and demonstrate clear value to patients, payors and physicians.”

The most common side effects of Januvia reported in clinical studies were stuffy or runny nose and sore throat, headache, diarrhea and joint pain.

For more information, log on to www.merck.com.


What are DPP-4 inhibitors?

DPP-4 inhibitors work by enhancing the body’s incretin system, which works to lower blood glucose. When blood glucose is elevated, incretins work in two ways to help the body regulate high blood glucose levels: They trigger the pancreas to increase insulin production, and they signal the liver to stop producing glucose. DPP-4 inhibitors enhance the body’s own ability to control blood glucose levels by increasing the active levels of incretin hormones in the body, helping to decrease blood glucose levels in patients with type 2 diabetes.

Source: Merck & Co., Inc.


Categories: Blood Glucose, Diabetes, Diabetes, Insulin, Januvia, Medications, Type 2 Issues, Type 2 Medications



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - May 1, 2006

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.